WO2001009173A3 - Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose - Google Patents

Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose Download PDF

Info

Publication number
WO2001009173A3
WO2001009173A3 PCT/FR2000/002194 FR0002194W WO0109173A3 WO 2001009173 A3 WO2001009173 A3 WO 2001009173A3 FR 0002194 W FR0002194 W FR 0002194W WO 0109173 A3 WO0109173 A3 WO 0109173A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparing
quinic
derivatives
mannose receptor
ligands
Prior art date
Application number
PCT/FR2000/002194
Other languages
English (en)
Other versions
WO2001009173A2 (fr
Inventor
Cyrille Grandjean
Oleg Melnyk
Helene Gras-Masse
Gerhild Angyalosi
Corinne Rommens
Claude Auriault
Original Assignee
Ct Nat De La Rech Scient Cnr
Pasteur Institut
Cyrille Grandjean
Oleg Melnyk
Gras Masse Helene
Gerhild Angyalosi
Corinne Rommens
Claude Auriault
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Nat De La Rech Scient Cnr, Pasteur Institut, Cyrille Grandjean, Oleg Melnyk, Gras Masse Helene, Gerhild Angyalosi, Corinne Rommens, Claude Auriault filed Critical Ct Nat De La Rech Scient Cnr
Priority to EP00956573A priority Critical patent/EP1200462A2/fr
Priority to AU68469/00A priority patent/AU6846900A/en
Priority to CA002388663A priority patent/CA2388663A1/fr
Priority to JP2001513979A priority patent/JP2003506335A/ja
Publication of WO2001009173A2 publication Critical patent/WO2001009173A2/fr
Publication of WO2001009173A3 publication Critical patent/WO2001009173A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à l'utilisation des acides quinique, shikimique et de leurs dérivés pour la préparation de ligands du récepteur du mannose, aux ligands ainsi préparés, ainsi qu'aux applications de ces ligands, notamment pour la préparation de médicaments et, plus particulièrement pour la préparation de vaccins et de médicaments destinés à assurer la vectorisation d'un principe actif vers des cellules cibles exprimant le récepteur du mannose ou un récepteur lui étant apparenté, la transfection de séquences d'ADN et d'ARN et ses multiples utilisations en thérapie génique, et la préparation de réactifs de laboratoire, notamment de réactifs de diagnostic.
PCT/FR2000/002194 1999-07-30 2000-07-28 Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose WO2001009173A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00956573A EP1200462A2 (fr) 1999-07-30 2000-07-28 Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose
AU68469/00A AU6846900A (en) 1999-07-30 2000-07-28 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands
CA002388663A CA2388663A1 (fr) 1999-07-30 2000-07-28 Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose
JP2001513979A JP2003506335A (ja) 1999-07-30 2000-07-28 マンノースレセプターリガンドを調製するためのキナ酸、シキミ酸およびそれらの誘導体の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9909928A FR2797441B1 (fr) 1999-07-30 1999-07-30 Derives des cyclohexane, cyclohexene, cyclohexadiene et benzene pour la preparation de ligands du recepteur du mannose
FR99/09928 1999-07-30

Publications (2)

Publication Number Publication Date
WO2001009173A2 WO2001009173A2 (fr) 2001-02-08
WO2001009173A3 true WO2001009173A3 (fr) 2001-08-16

Family

ID=9548718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/002194 WO2001009173A2 (fr) 1999-07-30 2000-07-28 Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose

Country Status (6)

Country Link
EP (1) EP1200462A2 (fr)
JP (1) JP2003506335A (fr)
AU (1) AU6846900A (fr)
CA (1) CA2388663A1 (fr)
FR (1) FR2797441B1 (fr)
WO (1) WO2001009173A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101245068A (zh) 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
CN101284799B (zh) 2007-03-23 2013-04-03 浙江医药股份有限公司新昌制药厂 咖啡酰奎宁酸含氮衍生物及其制备方法和其药物组合物及用途
CN101397333A (zh) 2007-09-27 2009-04-01 浙江医药股份有限公司新昌制药厂 去羟基万古霉素及其制备方法、和其药物组合物及其用途
CN101828693B (zh) 2009-03-09 2013-01-02 浙江医药股份有限公司新昌制药厂 制备低粘度高流动性类胡萝卜素油悬浮液的方法及其应用
AU2012216178A1 (en) * 2011-02-09 2013-08-22 Novozymes A/S Peptide for use in the treatment of skin conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019248A1 (fr) * 1991-05-03 1992-11-12 Washington University Ligands du recepteur de mannose a haute affinite
WO1995004541A1 (fr) * 1993-08-06 1995-02-16 Abbott Laboratories Analogues de lhrh a extremite n-terminale modifiee

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019248A1 (fr) * 1991-05-03 1992-11-12 Washington University Ligands du recepteur de mannose a haute affinite
WO1995004541A1 (fr) * 1993-08-06 1995-02-16 Abbott Laboratories Analogues de lhrh a extremite n-terminale modifiee

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AGNES MC E.A.: "Strongly increased efficiency of altered peptide ligands by mannosylation", INT.IMMUNOL., vol. 10, no. 9, September 1998 (1998-09-01), pages 1299 - 1304, XP000907255 *
GRANDJEAN, CYRILLE ET AL: "Convergent synthesis of D-(-)- quinic and shikimic acid-containing dendrimers as potential C-lectin ligands by sulfide ligation of unprotected fragments", J. CHEM. SOC., PERKIN TRANS. 1 (21 OCTOBER 1999), (20), 2967-2975, XP002137985 *
GRANDJEAN, CYRILLE ET AL: "Convergent synthesis of fluorescein-labeled lysine-based cluster glycosides", TETRAHEDRON LETT. (1999), 40(40), 7235-7238, XP004179025 *
SIMANEK E.A.: "Seletin-arbohyrate interactions: from natural ligands to designed mimics", CHEM.REV., vol. 98, no. 2, 1998, pages 833 - 862, XP002137984 *
TAN MC E.A.: "Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells", EUR.J.IMMUNOL., vol. 27, no. 9, September 1997 (1997-09-01), pages 2426 - 2435, XP000907259 *

Also Published As

Publication number Publication date
JP2003506335A (ja) 2003-02-18
FR2797441B1 (fr) 2001-10-12
CA2388663A1 (fr) 2001-02-08
WO2001009173A2 (fr) 2001-02-08
EP1200462A2 (fr) 2002-05-02
FR2797441A1 (fr) 2001-02-16
AU6846900A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
WO1995024485A3 (fr) EXPRESSION GENIQUE COORDONNEE $i(IN VIVO)
BG101103A (en) Mammalian telomerase
WO1996001614A3 (fr) Composant d'arn de la telomerase
GB2338484B (en) Medicaments comprising a nucleic acid encoding a cell targeting moiety and a prodrug activating enzyme
WO2001012659A3 (fr) Sequence d'adn humain
WO2003020949A3 (fr) Produits de recombinaison cibles d'acides nucleiques et utilisations en rapport avec lesdits produits
WO1998050554A3 (fr) POLYNUCLEOTIDES ET POLYPEPTIDES D'$i(ENTEROCOCCUS FAECALIS)
WO2001059459A3 (fr) Compositions et procedes de selection d'agents therapeutiques
WO2002064766A3 (fr) Genes reagissant a bax, destines a l'identification des cibles de medicaments dans la levure et les champignons
WO1998054313A3 (fr) Sequences genomiques d'adn methyltransferase et oligonucleotides antisens
WO2001009173A3 (fr) Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose
WO2001042495A3 (fr) Produits comprenant un support sur lequel sont fixes des acides nucleiques et leur utilisation comme puce a adn
AU3762699A (en) (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
Stix Shutting Down a Gene.
WO2001046463A3 (fr) Methodes de preparation et d'utilisation d'etalons internes destines a des dosages par amplification de l'acide nucleique
EP1277843A3 (fr) Nouveaux gènes humains et leurs produits d'expression liés au cancer du colon
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
WO2001049832A3 (fr) Transduction de recombinases pour ciblage genetique inductible
DE69226646D1 (de) Therapeutische Mittel
WO2001002550A3 (fr) Cibles de medicaments lies a la mort cellulaire dans des levures et des champignons
AU7974791A (en) Identification of novel drugs and reagents
CA2375549A1 (fr) Systeme d'apport de materiel biologique
WO2001041739A3 (fr) Liposomes
WO2001032693A3 (fr) Proteine mtr1 apparentee aux proteines trp et sequence adn codant pour celle-ci
WO2001044198A8 (fr) Polyamines amphiphiles, leurs utilisations et leur procede de synthese

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2388663

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 68469/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000956573

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000956573

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10048444

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000956573

Country of ref document: EP